HLA-G and neoplasm: Interestingly, hβ2m+ HLA-G5− tumors were rejected, whereas hβ2m+ HLA-G5+ tumors secreted soluble HLA-G, which protected them from hβ2m-elicited immune rejection, and grew similarly to a poorly immunogenic tumor.